Treatment
Carboplatin clinical trials
We’re tracking 483 recruiting studies that include Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT06575322Recruiting
Neoadjuvant therapy for head and neck cancer: effects on pain and mood
This trial tests whether adding immunotherapy to chemotherapy before surgery can help reduce pain, anxiety, and depression in people with head and neck cancer. The goal is to see if this approach improves quality of life during treatment.
Guanzhou, GuangdongAges 18–80 - NCT06576180Recruiting
Chemo-immunotherapy and cognition in head and neck cancer
This trial is studying whether a combination of chemotherapy (carboplatin and paclitaxel) and an immunotherapy drug (anti-PD-1) affects memory and thinking in people with head and neck cancer that can be removed with surgery. Researchers want to see if these treatments cause any cognitive changes.
Guanzhou, GuangdongAges 18–80 - NCT05942300RecruitingPhase 1
CPI-0209 plus platinum chemo for recurring ovarian cancer
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06637163RecruitingPhase 2
Study of benmelstobart plus chemo-radiation before surgery for esophageal cancer
This trial tests whether adding an immunotherapy drug (benmelstobart) to standard chemotherapy and radiation before surgery can help treat a certain type of esophageal cancer that can be surgically removed. The goal is to see if this combination is safe and works better than standard treatment alone.
Shantou, GuangdongAges 18 years+ - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06698965RecruitingPhase 2
Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06734182RecruitingPhase 2
Targeted therapy plus chemo before surgery for HER2-mutant lung cancer
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
GuangzhouAges 18–75 - NCT06830694RecruitingPhase 2
Trial of a new drug combo for a rare type of lung cancer
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Seoul, Gangnam-guAges 19 years+ - NCT07017673RecruitingPhase 2
Ivonescimab with chemo for early-stage triple negative breast cancer
This trial tests a new drug, ivonescimab, combined with standard chemotherapy before surgery for people with high-risk early-stage triple negative breast cancer. The goal is to see if adding this drug improves treatment response.
Los Angeles, CaliforniaAges 18 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT07043972RecruitingPhase 2
Gemcitabine and carboplatin after EV-pembrolizumab for bladder cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07108270RecruitingPhase 2
Study of dostarlimab plus chemotherapy for advanced or recurrent endometrial cancer
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
Jinan, ShandongAges 18 years+ - NCT07131319RecruitingPhase 2/Phase 3
Combination therapy for advanced lung cancer
This trial tests a new treatment combining stereotactic radiation (SFRT), the immunotherapy tislelizumab, and platinum chemotherapy for people with stage III non-small cell lung cancer that can't be removed with surgery. It aims to see if this combination helps shrink or control the cancer better.
Nanchang, JiangxiAges 18–85 - NCT07266493RecruitingPhase 2
Envafolimab plus chemo for esophageal cancer before surgery
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07283692RecruitingPhase 2
New drug combo for triple-negative breast cancer before surgery
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
ShanghaiAges 18–70 - NCT07285941RecruitingPhase 2
New targeted drug plus chemo for advanced ovarian cancer
This study tests whether a new targeted drug (distamab vedotin) combined with standard chemo (carboplatin) works better than chemo alone for women with advanced ovarian cancer that has high levels of HER2. It is for women who have not had chemotherapy yet and have already had surgery to remove the tumor.
Zhejiang, ZhejiangAges Any age - NCT07373964RecruitingPhase 2
Study of new drug combo for extensive-stage small-cell lung cancer
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Shenyang, LiaoningAges 18–75 - NCT07394387RecruitingPhase 2
HIFU with or without immunotherapy before chemo for triple-negative breast cancer
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Nanjing, JiangsuAges 18–70 - NCT02734069Recruiting
Testing whether muscle mass affects carboplatin side effects
This study looks at how your body’s “fat-free mass” (mostly muscle and organs) may change the dose of carboplatin and the risk of chemotherapy side effects. It’s for people with advanced lung cancer who are starting treatment with carboplatin plus paclitaxel for the first time.
Mexico CityAges 18 years+ - NCT07559045RecruitingPhase 2
Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Zunyi, GuizhouAges 18–75 - NCT07647094RecruitingEarly Phase 1
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT03025477RecruitingPhase 2
Testing two first-treatment options for advanced ovarian cancer
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
DijonAges 18–75 - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT07190248RecruitingPhase 3
Calderasib plus other treatments for advanced non-small cell lung cancer
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
Birmingham, AlabamaAges 18 years+
Common questions
- Are there clinical trials studying Carboplatin?
- Yes. Clin2 currently lists 483 recruiting studies that include Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.